FDA to approve photodynamics for lung cancer:
This article was originally published in Clinica
Executive Summary
Laserscope has obtained an approvable letter from the FDA for its photodynamic therapy in late-stage lung cancer. The FDA has already approved the technique for the much less common obstructive oesophageal cancers. In PDT, patients are endoscopically injected with porfimer sodium, a light-activated drug that is selectively absorbed by malignant cells. Another laser supplier, Coherent, has also applied for the same licence.